← All trials
NCT06824467
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 9, 2025
- Primary completion
- Apr 27, 2029
- Completion date
- Oct 15, 2032
- First posted
- Feb 13, 2025
- Last posted
- Oct 7, 2025
- Enrollment
- 770
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MerckLead sponsor
- GOG Foundation, Inc.Collaborator
- European Network for Gynaecological Oncological TrialCollaborator
- MerckOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.